Wall Street analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which indicates a positive year over year growth rate of 40.6%. The business is expected to report its next quarterly earnings results on Friday, April 6th.
On average, analysts expect that Intec Pharma will report full year earnings of ($1.35) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.89) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Wednesday, November 15th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.06).
Intec Pharma (NTEC) opened at $5.80 on Tuesday. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.
Several large investors have recently added to or reduced their stakes in NTEC. Caxton Corp acquired a new stake in shares of Intec Pharma in the third quarter worth $681,000. Sectoral Asset Management Inc acquired a new stake in Intec Pharma during the third quarter valued at $3,177,000. Finally, Pura Vida Investments LLC acquired a new stake in Intec Pharma during the third quarter valued at $895,000. Hedge funds and other institutional investors own 40.16% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.